MannKind (NASDAQ:MNKD) Price Target Raised to $4.75

MannKind (NASDAQ:MNKD) had its target price raised by investment analysts at Royal Bank Of Canada from $3.50 to $4.75 in a research note issued on Thursday,Benzinga reports. The firm currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 33.50% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Wedbush decreased their price objective on MannKind from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Thursday, March 5th. HC Wainwright upped their price objective on MannKind from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings cut MannKind from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday, March 2nd. Mizuho decreased their price target on MannKind from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 15th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.84.

MannKind Stock Down 0.1%

Shares of NASDAQ MNKD traded down $0.00 during mid-day trading on Thursday, reaching $3.56. 10,154,275 shares of the company were exchanged, compared to its average volume of 5,653,637. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of 178.84 and a beta of 1.04. MannKind has a 1 year low of $2.23 and a 1 year high of $6.51. The firm has a 50-day moving average of $2.77 and a 200 day moving average of $4.60.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The company had revenue of $90.17 million for the quarter, compared to analysts’ expectations of $105.38 million. MannKind had a negative return on equity of 11.21% and a net margin of 1.68%.The company’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.04 earnings per share. On average, equities analysts forecast that MannKind will post -0.02 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Michael Castagna acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $2.59 per share, with a total value of $259,000.00. Following the completion of the acquisition, the chief executive officer owned 2,575,911 shares of the company’s stock, valued at approximately $6,671,609.49. This trade represents a 4.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Level Four Advisory Services LLC increased its holdings in shares of MannKind by 12.5% in the third quarter. Level Four Advisory Services LLC now owns 17,333 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,925 shares during the period. Franklin Resources Inc. increased its holdings in shares of MannKind by 1.4% in the third quarter. Franklin Resources Inc. now owns 162,217 shares of the biopharmaceutical company’s stock valued at $871,000 after purchasing an additional 2,201 shares during the period. Aaron Wealth Advisors LLC increased its holdings in shares of MannKind by 1.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 200,763 shares of the biopharmaceutical company’s stock valued at $1,138,000 after purchasing an additional 2,355 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of MannKind by 7.8% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 33,405 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 2,404 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of MannKind by 6.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 39,234 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 2,443 shares during the period. 49.55% of the stock is owned by institutional investors and hedge funds.

MannKind News Summary

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: MannKind announced a collaboration with United Therapeutics to develop a dry‑powder inhalation (DPI) version of ralinepag for pulmonary hypertension and fibrotic lung diseases; United Therapeutics made an additional $5 million payment, will be the primary manufacturer, and MannKind is eligible for up to $35 million in development milestones plus 10% royalties — a potential multi‑year revenue stream and validation of MannKind’s inhalation platform. Ralinepag DPI Program
• Positive Sentiment: Mizuho cut its price target from $8 to $7 but kept an “outperform” rating, signaling that at least some analysts still see substantial upside from current levels — this can support bullish sentiment despite the cut. Mizuho Price Target Note
• Neutral Sentiment: MannKind posted its Q1 2026 presentation, press release and hosted an earnings call — useful for investors wanting management commentary on sales drivers, margins, and commercial execution. Q1 Slide Deck / Press Release
• Neutral Sentiment: Recent coverage and analysis (including a Seeking Alpha piece titled “MannKind: It’s Complicated”) discuss the company’s mixed fundamentals and strategic options — these pieces provide additional context but are interpretive rather than new corporate actions. It’s Complicated
• Negative Sentiment: Q1 results missed expectations: EPS of ($0.05) vs. consensus ($0.02) and revenue of $90.17M vs. $105.38M expected; while revenue rose year‑over‑year, the shortfall and a low net margin/negative ROE raise near‑term execution and profitability concerns. Q1 Miss / Zacks

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.